Omega Current Valuation

OMGA
 Stock
  

USD 6.30  0.30  4.55%   

Omega Therapeutics fundamentals help investors to digest information that contributes to Omega Therapeutics' financial success or failures. It also enables traders to predict the movement of Omega Stock. The fundamental analysis module provides a way to measure Omega Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Omega Therapeutics stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  

Omega Current Valuation Analysis

Omega Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value 
 = 
Market Cap + Debt 
-  
Cash 
More About Current Valuation | All Equity Analysis

Current Omega Therapeutics Current Valuation

    
  210.4 M  
Most of Omega Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Omega Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Compare to competition

In accordance with the recently published financial statements, Omega Therapeutics has a Current Valuation of 210.4 M. This is 98.54% lower than that of the Healthcare sector and 95.47% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 98.73% higher than that of the company.

Omega Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Omega Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Omega Therapeutics could also be used in its relative valuation, which is a method of valuing Omega Therapeutics by comparing valuation metrics of similar companies.
Omega Therapeutics is currently under evaluation in current valuation category among related companies.

Omega Fundamentals

About Omega Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Omega Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Omega Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Omega Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Omega Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 79 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Omega Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Omega Therapeutics' short interest history, or implied volatility extrapolated from Omega Therapeutics options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Omega Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Omega Therapeutics Piotroski F Score and Omega Therapeutics Altman Z Score analysis. Note that the Omega Therapeutics information on this page should be used as a complementary analysis to other Omega Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Piotroski F Score module to get Piotroski F Score based on binary analysis strategy of nine different fundamentals.

Complementary Tools for Omega Stock analysis

When running Omega Therapeutics price analysis, check to measure Omega Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Omega Therapeutics is operating at the current time. Most of Omega Therapeutics' value examination focuses on studying past and present price action to predict the probability of Omega Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Omega Therapeutics' price. Additionally, you may evaluate how the addition of Omega Therapeutics to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Is Omega Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omega Therapeutics. If investors know Omega will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omega Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
321.9 M
Return On Assets
(0.28) 
Return On Equity
(0.52) 
The market value of Omega Therapeutics is measured differently than its book value, which is the value of Omega that is recorded on the company's balance sheet. Investors also form their own opinion of Omega Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Omega Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omega Therapeutics' market value can be influenced by many factors that don't directly affect Omega Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omega Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Omega Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omega Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.